Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

Approval by European Commission would expand Reblozyl’s indication to include first-line treatment of anemia in adults with MDS in Europe


In the pivotal Phase 3 COMMANDS study, Reblozyl nearly...

Related Keywords

United States ,American ,Anne Kerber ,Bristol Myers Squibb ,Exchange Commission ,European Union ,Linkedin ,Instagram ,Head Of Late Clinical Development ,Youtube ,European Medicines Agency ,Committee For Medicinal Products Human Use ,Facebook ,Acceleron Pharma Inc ,Twitter ,European Commission ,Medicinal Products ,Human Use ,Late Clinical Development ,Cell Therapy ,Bristol Myers ,Hazard Ratio ,Confidence Interval ,North American ,Acceleron Pharma ,European Summary ,Product Characteristics ,Safety Information ,Prescribing Information ,Myers Squibb ,Better Future ,Looking Statement ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Markets ,